• LAST PRICE
    0.4252
  • TODAY'S CHANGE (%)
    Trending Up0.0104 (2.5072%)
  • Bid / Lots
    0.4251/ 2
  • Ask / Lots
    0.4349/ 5
  • Open / Previous Close
    0.4360 / 0.4148
  • Day Range
    Low 0.4200
    High 0.4360
  • 52 Week Range
    Low 0.2449
    High 4.0377
  • Volume
    114,187
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.4148
TimeVolumeRNLX
09:32 ET101180.4299
09:34 ET215740.425
09:36 ET4000.429
09:39 ET1000.4201
09:43 ET12510.42
09:48 ET1000.425
09:52 ET23250.429899
09:54 ET2000.429
09:56 ET6810.429
10:03 ET2000.4299
10:06 ET2000.43
10:08 ET7030.421
10:14 ET65070.4211
10:19 ET113350.421
10:21 ET3000.421
10:48 ET5600.425
10:51 ET1140.429951
11:08 ET17000.4301
11:27 ET10000.4301
11:36 ET81120.43
11:38 ET9000.43
11:40 ET2000.43
11:51 ET141880.4301
11:54 ET10000.4301
11:56 ET3280.4348
12:05 ET16640.4286
12:07 ET16000.425201
12:18 ET105000.4251
12:20 ET5000.4251
12:23 ET1690.4252
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRNLX
Renalytix PLC
32.4M
-0.5x
---
United StatesNMTC
Neuroone Medical Technologies Corp
25.6M
-1.6x
---
United StatesAKLI
Akili Inc
33.1M
-0.7x
---
United StatesPOSC
Positron Corp
29.8M
-12.8x
---
United StatesICCM
Icecure Medical Ltd
51.3M
-3.3x
---
United StatesCODX
Co-Diagnostics Inc
32.8M
-0.8x
---
As of 2024-06-03

Company Information

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Contact Information

Headquarters
Finsgate, 5-7 Cranwood StreetLONDON, United Kingdom EC1V 9EE
Phone
292-071-0570
Fax
---

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$32.4M
Revenue (TTM)
$2.2M
Shares Outstanding
77.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.89
EPS
$-0.78
Book Value
$0.15
P/E Ratio
-0.5x
Price/Sales (TTM)
14.6
Price/Cash Flow (TTM)
---
Operating Margin
-1,531.61%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.